Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
7 stopped studies mapped to Bronchogenic Carcinoma and descendants · 100% state a reason
Over the 7 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | N/A | terminated | Sep 25, 2018 | University Hospital, Toulouse | recruitment difficulties | Enrollment / accrual |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced…(AcceleRET-Lung) | Phase 3 | terminated | Jan 10, 2020 | Hoffmann-La Roche | Early termination of the study resulted from organizational and commercial decisions that led to… | Other (stated, no rule matched) |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Phase 1 | terminated | Apr 28, 2021 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Phase 1 | terminated | Feb 16, 2022 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy… | Phase 2 | withdrawn | Aug 4, 2021 | National Cancer Institute (NCI) | Due to no accrual | Enrollment / accrual |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Phase 1 | terminated | Dec 10, 2021 | Blueprint Medicines Corporation | Lack of efficacy | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 6, 2026source: clinicaltrials